Actavis has an eye on more deals, for 'couple billion dollars' or so

Actavis CEO Brent Saunders

Actavis ($ACT), still awaiting the close of its $66 billion buyout of Allergan ($AGN), is on the lookout for more bolt-on acquisitions. As CEO Brent Saunders told Bloomberg, the company isn't up for any transformational deals in the short term, instead looking for buyouts in the "couple billion dollar" range. More

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.